NCT00806754

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 340 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

* The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intranasal corticosteroid or antihistamine monotherapy * The secondary objective is to investigate the safety of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray

Conditions

• Rhinitis, Allergic, Perennial

Interventions

Type	Name	Description
DRUG	Ciclesonide nasal spray + placebo Azelastine	Ciclesonide nasal spray 50 mcg + Placebo Azelastine
DRUG	Ciclesonide nasal spray + Azelastine	Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg

Timeline

• Start date: 2006-11-01
• Primary completion: 2007-05-01
• Completion: 2007-08-01
• First posted: 2008-12-11
• Last updated: 2016-11-23

Locations

35 sites across 1 country: United States